Plain-English translation of NCT07093476 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether — a medication that works differently than drugs you may already be taking — can help lower blood sugar when added to your current diabetes treatment. Right now, you're likely taking and together, but your blood sugar still isn't where your doctor wants it to be. Researchers want to see if this medication can help.
Many people with type 2 diabetes don't reach their blood sugar goals with just two medications. This study is trying to find out if adding this medication to your existing treatment plan can give you better control without causing safety concerns.
You likely qualify if…
You likely don't qualify if…
You will continue taking your current diabetes medications ( and ), and researchers will randomly assign you to either take the new medication at one dose, take it at a different dose, or stay on your current two drugs without adding anything. You'll visit the clinic for check-ups and blood tests to see how well your blood sugar is controlled and to make sure the medication is safe for you.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
South Korea
Large-scale testing
Sponsor
Celltrion
Enrollment target
~171 participants
Started
July 2025
Primary completion
December 2026
Age range
19 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Celltrion, Inc.
Celltrion
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.